###### Strengths and limitations of this study

-   This is an analysis of a large multicentre chart review study from 23 emergency departments (EDs) across Japan.

-   As with observational study, the lack of association between nocturnal ED visits and risk of hospitalisation might be confounded by unmeasured factors, such as the time of onset of asthma exacerbation and institutional variation in resource usage.

-   Our inferences may not be generalisable to rural or non-academic EDs or other healthcare settings outside of Japan.

Introduction {#s1}
============

Asthma is an inflammatory disease of the airways and frequently characterised by marked changes in symptoms according to a circadian rhythm. More than two-thirds of patients with asthma experience nocturnal exacerbations.[@R1] It has been speculated that the treatment of patients presenting to the emergency department (ED) with asthma exacerbation may be less successful at the night-time than during the other times of the day because acute asthma severity increases at night.[@R4] However, other studies from North America have failed to demonstrate a consistent relationship between nocturnal visits to the ED and poor outcomes, such as an increased risk of hospitalisation.[@R5] In addition, to the best of our knowledge, the relationship between the time of the ED presentation and acute outcomes of asthma exacerbation has not been studied in other settings (eg, Asian countries).

To address the knowledge gap in the literature, using the data from a multicentre study, we aimed to compare the characteristics of patients presenting to the ED for asthma exacerbation at the night-time (between midnight and 07:59) with those of patients presenting at the other times of the day (between 08:00 and 23:59), and to investigate whether the time of ED presentation is associated with the risk of hospitalisation for asthma exacerbation.

Methods {#s2}
=======

Study design and settings {#s2a}
-------------------------

This is a secondary analysis of a multicentre chart review study to characterise adult patients with asthma exacerbation and their management in 23 EDs across Japan.[@R9] [@R10] This study was coordinated by the Japanese Emergency Medicine Network (JEMNet) in collaboration with the US-based Emergency Medicine Network (<http://www.emnet-usa.org>). The JEMNet (<http://jemnet.asia/wp>) is a consortium of 23 academic and community hospitals from different geographic regions across Japan. During the period of this study, all of the EDs were staffed by ED-based attending physicians. The study was approved by the Institutional Review Board of each participating centre (see the Acknowledgements section)' and Massachusetts General Hospital.

Study population {#s2b}
----------------

Using the *International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM)* code J45.xx, each participating hospital identified all ED visits with a principal ED or hospital discharge diagnosis of asthma from hospital administrative records from 1 January 2009 through 1 December 2011. Patients aged 18--54 years, with a history of physician-diagnosed asthma before the index ED visit were eligible for the analysis. We excluded ([@R1]) visits made by patients with a history of physician-diagnosed chronic obstructive pulmonary disease (COPD), emphysema or chronic bronchitis, (2) transfer visits, (3) repeat visits by the same patient or (4) visits not largely prompted by an asthma exacerbation. In the case of repeat visits, only the first ED visit during the study period was included in the analysis.

Data collection and measurements {#s2c}
--------------------------------

Onsite chart abstractors reviewed 60 randomly selected ED charts from January to December 2011. If sites had \<60 charts during this period, the abstractors reviewed eligible charts dating back to January 2009 in order to reach the target. All chart abstractors were emergency physicians or emergency medicine residents who had been trained in a 1-hour online lecture. They were required to complete practice charts, which were assessed against a 'criterion standard'; those whose accuracy was \<80% per chart had to be retrained.

The following data were abstracted using a standardised form: patients' demographics, chronic asthma characteristics, asthma exacerbation presentation, management in the ED and at discharge, and ED disposition. This standardised form has been used in multiple US-based studies conducted by the Emergency Medicine Network.[@R6] [@R9]

Outcome measures {#s2d}
----------------

The outcome of interest was hospitalisation, defined by an admission to an observation unit, inpatient unit and intensive care unit.

Statistical analysis {#s2e}
--------------------

For the purpose of this analysis, patients were categorised into two groups according to their time at ED presentation:[@R6] the night-time (between midnight and 07:59) and the other times (between 08:00 and 23:59). First, the unadjusted association of the time of ED presentation with the patient characteristics and ED management was examined using the χ^2^ test and Mann-Whitney U test, as appropriate. Next, to examine the association of the time of ED presentation with the risk of hospitalisation, we fitted a multivariable logistic regression model adjusting for eight potential confounders that were selected based on a priori knowledge and clinical plausibility: age, sex, comorbidity, history of intubation for asthma, history of ED visits over the last year, history of hospitalisations for asthma in the last year and the current use of inhaled corticosteroids and leukotriene modifiers.

Missing indicator methods were used to address missing data. ORs were presented with 95% CIs. Statistical analyses were performed using JMP V.10.0 software (SAS Institute, Cary, North Carolina, USA) and all tests were two-tailed using a statistical significance value of p\<0.05.

Results {#s3}
=======

We identified 1380 patients who presented to one of the 23 EDs with asthma exacerbation. Of these, we excluded 26 patients who had missing data on the time of ED presentation (non-analytic cohort), and the remaining 1354 patients (98%) had data on the time of ED presentation (analytic cohort), and were included in the current analysis. The analytic and non-analytic cohorts had similar demographics, chronic asthma characteristics, ED presentation and ED disposition (all p\>0.05; data not shown).

Demographic characteristics and chronic asthma factors {#s3a}
------------------------------------------------------

Overall, the median age was 35 years (IQR, 26--43 years), 42% were male and 11% were hospitalised to the ED. Of 1354 patients in the analytic cohort, 408 (30%) presented to the ED at the night-time (the night-time group) and 946 (70%) at the other times (the other time group). There were no significant differences in the demographic characteristics, chronic asthma characteristics or current asthma medications between the two groups ([table 1](#BMJOPEN2015010670TB1){ref-type="table"}).

###### 

Demographic characteristics, chronic asthma factors and emergency department (ED) course of patients with asthma exacerbation, according to the time of ED presentation

  ----------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                                                                     Midnight--07:59(night-time)\   08:00--23:59 (other times)\   p Value
                                                                                n=408 (30%)                    n=946 (70%)                   
  ----------------------------------------------------------------------------- ------------------------------ ----------------------------- ---------
  Demographics                                                                                                                               

   Age (year), median (IQR)                                                     34 (26--42)                    35 (26--43)                   0.55

   Female sex                                                                   224 (55%)                      571 (60%)                     0.06

   Not pregnant\*                                                               165 (90%)                      423 (93%)                     0.32

   Comorbidity                                                                  37 (9%)                        114 (12%)                     0.11

   Age at the diagnosis of asthma (year), median (IQR)                          19 (6--30)                     20 (9--30)                    0.29

   Current smoking                                                              130 (45%)                      268 (40%)                     0.07

  Chronic asthma factors                                                                                                                     

   History of intubation for asthma                                             10 (4%)                        11 (2%)                       0.08

   History of hospitalisation for asthma                                        95 (37%)                       189 (33%)                     0.30

   Ever use of systemic corticosteroids                                         113 (52%)                      266 (50%)                     0.62

   ED visit for asthma in last year                                             70 (25%)                       144 (21%)                     0.15

   Hospitalised for asthma in last year                                         26 (8%)                        52 (7%)                       0.58

   Current use of inhaled corticosteroids                                       113 (29%)                      290 (33%)                     0.15

   Current use of oral methylxanthines                                          49 (12%)                       99 (11%)                      0.54

   Current use of leukotriene modifiers                                         51 (13%)                       96 (11%)                      0.30

  Presentation and ED course                                                                                                                 

   Duration of symptoms before ED arrival                                                                                                    \<0.001

    ≤3 hours                                                                    103 (26%)                      122 (13%)                     

    4--11 hours                                                                 103 (26%)                      181 (20%)                     

    12--24 hours                                                                77 (20%)                       219 (24%)                     

    1--3 days                                                                   71 (18%)                       244 (27%)                     

    4--7 days                                                                   24 (6%)                        93 (10%)                      

    \>7 days                                                                    19 (5%)                        51 (6%)                       

   Prehospital treatment                                                        45 (12%)                       110 (12%)                     0.64

    Initial respiratory rate (breaths/min), median (IQR)                        21 (18-25)                     20 (18-24)                    0.13

    Initial oxygen saturation on room air (%), median (IQR)                     96 (93-98)                     96 (94-98)                    0.03

    Initial PEF (L/min), median (IQR)†                                          205 (143-258)                  200 (150-290)                 0.61

    Number of inhaled β-agonists in 1 hour from ED presentation, median (IQR)   1 (1-2)                        1 (1-2)                       0.09

    Number of inhaled β-agonists in ED, median (IQR)                            1 (1-2)                        1 (1-2)                       0.38

    Systemic corticosteroids in ED                                              160 (39%)                      409 (43%)                     0.17

    Intravenous magnesium in ED                                                 5 (1%)                         9 (1%)                        0.65

  ED disposition                                                                                                                             0.62

   Observation unit                                                             5 (1%)                         9 (1%)                        

   Hospital ward                                                                37 (9%)                        81 (9%)                       

   Intensive care unit                                                          4 (1%)                         9 (1%)                        

   Sent home‡                                                                   356 (87%)                      841 (89%)                     

   Others (eg, left against medical advice)                                     6 (2%)                         6 (1%)                        
  ----------------------------------------------------------------------------------------------------------------------------------------------------

Data were presented as number (%) unless otherwise indicated.

\*Analysed for 183 (44.9%) female patients in the night-time group and 457 (48.3%) female patients in the other group.

†Analysed for 32 (7.8%) patients in the night-time group and 77 (8.1%) patients in the other time group with initial PEF available.

‡Analysed for 356 (87.3%) patients in the night-time group and 841 (88.9%) patients in the other time group who were discharged to home.

ED, emergency department; PEF, peak expiratory flow.

ED course of patients with asthma exacerbation {#s3b}
----------------------------------------------

Asthma exacerbation presentation and ED course, according to the time of ED presentation, are shown in [table 1](#BMJOPEN2015010670TB1){ref-type="table"}. Patients in the night-time group were more likely to have a shorter duration of symptoms (≤3 hours) prior to their ED presentation compared to those in the other time group (26% vs 13%; p\<0.001). However, there were no significant differences in the presentation (eg, respiratory rate, initial peak expiratory flow) or acute asthma treatment in the ED between the groups. Similarly, the proportion of the patients hospitalised from the ED did not differ significantly between the two groups (11% vs 11%; p=0.65). Likewise, in the multivariable logistic regression model adjusting for eight potential confounders, the time of ED presentation was not associated with the risk of hospitalisation (OR for night-time vs other times, 1.10; 95% CI 0.74 to 1.61; p=0.63; [table 2](#BMJOPEN2015010670TB2){ref-type="table"}).

###### 

Unadjusted and adjusted association of time of emergency department presentation with risk of hospitalisation

  ------------------------------------------------------------------------------------------------
  Time of ED presentation   Unadjusted analysis\   p Value   Multivariable analysis\*\   p Value
                            OR (95% CI)                      OR (95% CI)                 
  ------------------------- ---------------------- --------- --------------------------- ---------
  08:00--23:59              1.00 (reference)       --        1.00 (reference)            --

  Midnight--07:59           1.09 (0.75 to 1.57)    0.65      1.10 (0.74 to 1.61)         0.63
  ------------------------------------------------------------------------------------------------

\*Multivariable analysis adjusted for age, sex, comorbidity, history of intubation for asthma, history of admissions for asthma in the last year, history of ED visits over the last year, current use of inhaled corticosteroids and leukotriene modifiers.

ED, emergency department.

Discussion {#s4}
==========

In this multicentre study of 1354 ED patients with asthma exacerbation, ∼30% of the patients presented to the ED at the night-time. These patients presented to the ED with a shorter duration of symptoms compared to those who presented to the ED at the other times. In contrast, our data did not indicate any circadian difference in the risk of hospitalisation in ED patients with asthma exacerbations.

Results in context {#s4a}
------------------

Despite the clinical importance, few studies have examined the relationship of clinical characteristics of asthma exacerbation with nocturnal asthma in the recent years. Several studies have reported that patients with nocturnal asthma had a higher morbidity and inhospital mortality compared to others.[@R4] [@R17] In contrast, in agreement with our observations, previous North American studies of ED patients with asthma exacerbation did not find a significant association between the time of ED presentation and the risk of hospitalisation.[@R6] For example, Brenner *et al*,[@R6] by analysing the data of a multicentre prospective cohort of 2494 ED adult patients (aged 18--54 years) with asthma exacerbation in the USA and Canada, reported no association between nocturnal visits and risks of hospitalisation. The reasons for the apparent discrepancies between the studies are likely multifactorial---for example, the differences in study design, patient population, setting or any combination of these factors. Indeed, the aforementioned studies that reported a higher morbidity in patients with nocturnal asthma were conducted in the inpatient setting[@R17] [@R19] while the studies that demonstrated the lack of morbidity association,[@R6] including our work, were conducted in the ED setting. These ED data from different healthcare systems (the USA, Canada and Japan) collectively suggest that nocturnal ED visits for asthma exacerbation may not be associated with the more-severe acute asthma outcomes in ED patients, unlike such cases in hospitalised patients.

Alternatively, non-biological factors, such as access to healthcare including primary and asthma specialist care, patient health behaviours, use of long-term controllers and chronic and acute severity of asthma, also are likely to have contributed to the discrepancy. Indeed, in our study, the proportion of inhaled corticosteroid use prior to the ED visit (32%) was higher than the previous studies, although it remained suboptimal. The higher proportion of patients with long-term controller use in our study might also have affected the acute asthma severity and response to therapy, and further contributed to the absence of significant association between the nocturnal ED visits for asthma exacerbation and the risk of hospitalisation. Our multicentre study of a large number of ED adults builds on these prior studies that examined the risk of hospitalisation by time of ED presentation and extends them by conducting a multicentre study in Japan.

Potential limitations {#s4b}
---------------------

We acknowledge several potential limitations of this study. First, this multicentre study relied on chart review for data collection, and hence errors in data measurement are possible. However, we used a previously applied standardised data collection system with uniform definitions and rigorous training, which achieved a high interobserver agreement (κ-statistics, 0.56--1.00 (moderate-to-perfect agreement)).[@R9] Second, our study had no information on the reasons for nocturnal ED visits. Third, as with any observational study, the lack of association between nocturnal ED visits and risk of hospitalisation might be confounded by unmeasured factors, such as the time of onset of asthma exacerbation and institutional variation in resource usage. Indeed, in this multicentre study, we did not standardise criteria for hospitalisation across the 23 participating EDs. Fourth, the limited age range (18--54 years) in this study may limit the generalisability of our findings. However, we chose this age range to limit a potential contamination of older patients with COPD or asthma-COPD overlap syndrome that may bias the inferences. Finally, our sample consisted predominantly of urban, academic EDs in Japan. Our study population had a relatively high chronic severity burden (eg, 22% of patients had at least one ED visit for asthma in the preceding year) and high acute severity (eg, 8% resulted in hospitalisation), although these proportions were lower than those in the recent multicentre study from the USA.[@R20] In addition, the participating EDs provided acute asthma care that was imperfectly concordant to the recommendations in the asthma guidelines.[@R9] Therefore, our inferences may not be generalisable to rural or non-academic EDs or other healthcare settings outside of Japan. Nevertheless, multiple studies arrived at a similar conclusion (ie, no association between the time of ED presentation and risk of hospitalisation), despite differing populations and healthcare settings,[@R6] potentially enhancing the generalisability of our inferences.

Conclusion {#s4c}
==========

In this multicentre analysis of 1354 ED patients with asthma exacerbation, we found that many patients presented to the ED at the night-time. Our data also demonstrated no significant difference in the risk of hospitalisations according to the time of ED presentation. The reasons for nocturnal ED visits for asthma exacerbation are multifactorial---for example, acute asthma severity, access to the healthcare system and patient behaviour. Our data should facilitate further investigation to disentangle the complex web of these factors.
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